• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在日本，10 名感染 SARS-CoV-2 奥密克戎变异株突破性感染的患者的中和活性和抗体滴度。

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.

机构信息

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

出版信息

J Infect Chemother. 2022 Sep;28(9):1340-1343. doi: 10.1016/j.jiac.2022.04.018. Epub 2022 Apr 22.

DOI:10.1016/j.jiac.2022.04.018
PMID:35644734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9023325/
Abstract

The Omicron variant of severe acute respiratory syndrome coronavirus 2 has multiple amino acid mutations in its spike proteins, which may allow it to evade immunity elicited by vaccination. We examined the neutralising activity and S1-IgG titres in patients with breakthrough infections caused by the Omicron variant after two doses of vaccination. We found that neutralising activity was significantly lower for the Omicron variant than for the Wuhan strain. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant.

摘要

奥密克戎变异株严重急性呼吸综合征冠状病毒 2 在其刺突蛋白上有多个氨基酸突变，这可能使其能够逃避疫苗接种引起的免疫。我们研究了两剂疫苗接种后奥密克戎变异株突破性感染患者的中和活性和 S1-IgG 滴度。我们发现，奥密克戎变异株的中和活性明显低于武汉株。两剂疫苗接种可能不会诱导对奥密克戎变异株产生足够的中和活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/56147345b945/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/502527ffebb4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/117bf226a739/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/56147345b945/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/502527ffebb4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/117bf226a739/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906f/9023325/56147345b945/gr3_lrg.jpg

相似文献

1
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.在日本，10 名感染 SARS-CoV-2 奥密克戎变异株突破性感染的患者的中和活性和抗体滴度。
J Infect Chemother. 2022 Sep;28(9):1340-1343. doi: 10.1016/j.jiac.2022.04.018. Epub 2022 Apr 22.
2
Two Cases of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections Caused by the Omicron Variant (B.1.1.529 Lineage) in International Travelers to Japan.两例入境日本的国际旅行者感染奥密克戎变异株（B.1.1.529 谱系）导致的突破性严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染
Clin Infect Dis. 2022 Aug 24;75(1):e354-e356. doi: 10.1093/cid/ciab1072.
3
Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022.2022 年 6 月至 9 月，在以色列，接种疫苗的个体在 BA.1 和 BA.5 突破感染后，能够有效地中和奥密克戎 BA.2.75 变体。
Euro Surveill. 2022 Nov;27(44). doi: 10.2807/1560-7917.ES.2022.27.44.2200785.
4
Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.奥密克戎变异株对儿童自然感染 SARS-CoV-2 或接种 COVID-19 疫苗诱导产生的中和抗体的敏感性。
Emerg Microbes Infect. 2022 Dec;11(1):543-547. doi: 10.1080/22221751.2022.2035195.
5
Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.在接受三剂新冠病毒mRNA疫苗后，实体器官移植受者针对包括奥密克戎在内的新冠病毒变异株的体液免疫。
Clin Transl Immunology. 2022 Apr 29;11(5):e1391. doi: 10.1002/cti2.1391. eCollection 2022.
6
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.新型关注变异株 SARS-CoV-2 奥密克戎（B.1.1.529）的特征及其全球视角。
J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.
7
RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants.德尔塔和奥密克戎变异株导致的突破性新冠肺炎患者体内的严重急性呼吸综合征冠状病毒 2 的 RNA 载量。
Clin Microbiol Infect. 2023 Feb;29(2):256.e1-256.e4. doi: 10.1016/j.cmi.2022.09.003. Epub 2022 Sep 15.
8
A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.SARS-CoV-2 德尔塔变异株突破性感染及家庭传播病例报告：疫苗接种、抗刺突 IgG 及中和活性的作用。
J Infect Chemother. 2022 Jul;28(7):962-964. doi: 10.1016/j.jiac.2022.02.003. Epub 2022 Feb 11.
9
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.鼻腔递送广谱中和抗体可保护小鼠免受 SARS-CoV-2 德尔塔和奥密克戎变异株的致死性攻击。
Virol Sin. 2022 Apr;37(2):238-247. doi: 10.1016/j.virs.2022.02.005. Epub 2022 Feb 18.
10
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.

引用本文的文献

1
Large-scale screening of SARS-CoV-2 variants in Tokyo, Japan: A 3-year and 9-month longitudinal survey.日本东京新型冠状病毒变异株的大规模筛查：一项为期3年9个月的纵向调查。
Glob Health Med. 2025 Apr 30;7(2):151-160. doi: 10.35772/ghm.2025.01004.

本文引用的文献

1
The first eleven cases of SARS-CoV-2 Omicron variant infection in Japan: A focus on viral dynamics.日本首批11例新型冠状病毒奥密克戎变异株感染病例：聚焦病毒动态。
Glob Health Med. 2022 Apr 30;4(2):133-136. doi: 10.35772/ghm.2021.01124.
2
Plasma Neutralization of the SARS-CoV-2 Omicron Variant.新冠病毒奥密克戎变异株的血浆中和作用
N Engl J Med. 2022 Feb 10;386(6):599-601. doi: 10.1056/NEJMc2119641. Epub 2021 Dec 30.
3
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.奥密克戎能广泛但不完全地逃避辉瑞 BNT162b2 的中和作用。
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.
4
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.奥密克戎变异株（B.1.1.529）：传染性、疫苗突破和抗体耐药性。
J Chem Inf Model. 2022 Jan 24;62(2):412-422. doi: 10.1021/acs.jcim.1c01451. Epub 2022 Jan 6.
5
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.BNT162b2 疫苗接种者中和/SARS-CoV-2-S1 结合抗体反应与不良反应和免疫动力学的相关性。
Sci Rep. 2021 Nov 24;11(1):22848. doi: 10.1038/s41598-021-01930-y.
6
Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections.SARS-CoV-2 免疫逃逸 Spike 变异对二次感染和疫苗突破感染的影响。
Front Immunol. 2021 Nov 3;12:742167. doi: 10.3389/fimmu.2021.742167. eCollection 2021.
7
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.SARS-CoV-2 多克隆中和抗体逃逸的高遗传屏障。
Nature. 2021 Dec;600(7889):512-516. doi: 10.1038/s41586-021-04005-0. Epub 2021 Sep 20.
8
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.用 COVID-19 恢复期患者血浆中的 IgG 中和 SARS-CoV-2。
Sci Rep. 2021 Mar 10;11(1):5563. doi: 10.1038/s41598-021-84733-5.
9
A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies.一种新型高灵敏度和重现性的抗 SARS-CoV-2 IgG 和 IgM 抗体检测方法。
Sci Rep. 2021 Mar 4;11(1):5198. doi: 10.1038/s41598-021-84387-3.
10
Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM.冷冻电镜解析 SARS-CoV-2 三聚体刺突糖蛋白与受体 ACE2 复合物的构象动态。
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abe5575. Print 2021 Jan.